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Introduction: A second generation HPV vaccine has been developed for the prevention of anogenital
cancers and precancerous lesions of the cervix, vulva, vagina, anus and of genital warts due to nine
HPV types.
We estimated the annual burden of these diseases attributable to the nine HPV types compared to
HPV types from ﬁrst generation vaccines in women and men in Europe.
Material and methods: Incidence rates from the IARC database, cancer registries, the literature and
Eurostat population data were used.
The burden attributable to the HPV types targeted by both vaccines was estimated by applying the
relative contribution of the respective HPV types from epidemiological studies.
Results: In 2013, the number of new anogenital HPV-attributable cancers was 44,480 with 39,494 of
these cases related to second vs. 33,285 to ﬁrst generation vaccine types.
Among the 284,373 to 541,621 new HPV-attributable anogenital precancerous lesions 235,364–
448,423 and 135,025–256,830 were estimated to be related to second and ﬁrst generation vaccine types,
respectively.
The annual number of new genital warts was 753,608–935,318, with 90% related to HPV6/11.
Conclusions: These data demonstrate how the large public health impact that was achieved by the ﬁrst
generation HPV vaccines could be further increased by second generation vaccines.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The discovery of human papillomavirus (HPV) as the necessary
cause of cervical cancer has led to the development of different
prophylactic HPV vaccines. The International Agency for Research
on Cancer (IARC) has identiﬁed twelve HPV types as carcinogenic
to humans: HPV16/18/31/33/35/39/45/51/52/56/58/59 [1]. In addi-
tion to cervical cancer, HPV is responsible for a signiﬁcant
proportion of cancers and precancerous lesions of the vulva,
vagina, and anus in women; cancers and precancerous lesions of
the anus and penis in men; and a subset of head and neck cancers
and genital warts in both sexes.
Two HPV vaccines have been licensed so far in Europe: the
quadrivalent HPV vaccine, Gardasil® 9 (Sanoﬁ Pasteur MSD)/
Silgards (Merck Sharp & Dohme), and the bivalent HPV vaccine,
Cervarixs (GlaxoSmithKline Biologicals). Both vaccines have reas-
suring safety proﬁles, as demonstrated in clinical trials, and are
indicated for the prevention of cervical, vulvar and vaginal
premalignant lesions and cervical cancer related to HPV16/18.
The quadrivalent HPV vaccine is also indicated against premalig-
nant anal lesions and anal cancer and protects against low-risk
HPV6/11, which are responsible for about 90% of genital warts [2]
and a fraction of precancerous lesions.
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As it takes several decades for HPV infection to progress to
cancer, it will be some time before the real effects of current
HPV vaccination programs will be seen in terms of a reduced
incidence of HPV-related cancers. In the meantime, in countries
like Australia, where vaccination coverage is high, a reduction of
77% in the prevalence of infections with the HPV types targeted
by the vaccines has been observed in young women [3], along with a
92.6% reduction in the incidence of genital warts (ptrendo0.0001)
[4]. Moreover, just 3 years after the implementation of the
HPV vaccination program in Australia, the incidence of high-grade
cervical precancerous lesions in women under 18 years of age
decreased, from 0.85% in 2006 (1 year before vaccine introduction)
to 0.22% in 2009 (p¼0.003) [5]. This ecological observation
was conﬁrmed in two recent studies. One was a data-linkage
study [6] that reported an adjusted vaccine effectiveness of 47.5%
(95% conﬁdence interval [CI]: 22.7–64.4%) to prevent cervical
intraepithelial neoplasia (CIN) grade 3/adenocarcinoma in situ or
worse among women who received all required doses of the
quadrivalent vaccine (i.e., were fully vaccinated). The other study
[7] reported a vaccine effectiveness of 46% (95% CI: 33–57%) for
histologically conﬁrmed high-grade cervical precancerous lesions
among young women who were fully vaccinated before they
initiated cervical cancer screening. Additionally, as a reﬂection of
herd immunity, there has been a signiﬁcant reduction in the
frequency of genital warts in young men. In Australia, where there
is an estimated 83% coverage of the ﬁrst dose of HPV vaccine in girls
aged 12–13 years, the reduction in the proportion of new genital
warts cases among young menwas in the order of 60% [8,9]. In 2013,
Australia became the ﬁrst country to implement a school-based
vaccination program for boys aged 12–13 years. Currently the United
States, Ireland, New Zealand, and Canada are also recommending
HPV vaccination for boys.
After HPV16/18, high-risk HPV31/33/35/45/52/58 are the six
most frequently detected HPV types in invasive cervical cancer
worldwide [10]. Merck has developed a second generation nine-
valent HPV L1 virus-like particle vaccine (Gardasil® 9), which aims
to protect against the seven high-risk HPV types (HPV16/18/31/33/
45/52/58) most frequently responsible for cervical cancer devel-
opment worldwide, and the low-risk HPV types (HPV6/11) respon-
sible for about 90% of genital warts. Thus, the nine-valent vaccine
is designed to protect against ﬁve ‘new’ high-risk HPV types
(HPV31/33/45/52/58) that are not targeted by the quadrivalent
or the bivalent vaccine. The vaccine is indicated to protect against
premalignant lesions and cancers affecting the cervix, vulva,
vagina and anus caused by vaccine HPV types as well as genital
warts caused by speciﬁc HPV types.
In a Phase III study, the nine-valent vaccine prevented 97% of
high-grade precancerous lesions of the cervix, vulva, and vagina
caused by the ﬁve new high-risk HPV types (HPV31/33/45/52/58)
[11]. The nine-valent vaccine also generated immune responses to
HPV6/11/16/18 that were as good as or better than those generated
by the quadrivalent vaccine.
The aim of this study was to estimate the annual burden of
selected cancers, precancerous lesions, and genital warts attribu-
table to the HPV types targeted by the second generation nine-
valent HPV vaccine Gardasil 9s (high-risk HPV16/18/31/33/45/52/
58, low-risk HPV6/11) in women and men in Europe in 2013, and
to compare this to the estimated annual burden of the same
lesions related to the HPV types targeted by the ﬁrst generation
HPV vaccines.
National registries
Regional registries
Extrapolated from 
neighbouring 
countries
Fig. 1. Selected countries: European Medicines Agency region and Switzerland (32 countries).
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2. Material and methods
2.1. Estimation of the annual burden of cancer in Europe
The Cancer Incidence in Five Continents (CI5) database, avail-
able on the IARC website [12], contains worldwide data on cancer
incidence rates classiﬁed by International Classiﬁcation of Diseases
10th Revision (ICD-10) codes. These data are obtained from
regional or national registries, depending on the country, but to
be included in CI5 these registries must meet the IARC’s quality
criteria, i.e., they must have reliable cancer registry data. The
present report includes cancer incidence data from CI5 Volume X,
which were collected from 2003 throughout 2007. We selected a
total of 32 countries: all 31 countries covered by the European
Medicines Agency (Austria, Belgium, Bulgaria, Croatia, Cyprus, the
Czech Republic, Denmark, Estonia, Finland, France, Germany,
Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein,
Lithuania, Luxemburg, Malta, the Netherlands, Norway, Poland,
Portugal, Romania, Slovenia, Slovakia, Spain, Sweden, and the
United Kingdom) plus Switzerland.
The information in CI5 Volume X was obtained from national
cancer registries for Belgium, Bulgaria, Croatia, Cyprus, the Czech
Republic, Denmark, Estonia, Finland, Iceland, Ireland, Latvia, Lithua-
nia, Malta, the Netherlands, Norway, Slovenia, Slovakia, and Swe-
den. The information in CI5 Volume X was obtained from regional
cancer registries for Austria, France, Germany, Italy, Poland, Portu-
gal, Spain, Switzerland, and the United Kingdom (Fig. 1).
To ensure that national populations were adequately represented
in countries where only regional cancer registries exist, we assessed
the geographical coverage and distribution of these registries.
Five of the 32 countries selected did not have data available in
CI5 Volume X, as they did not have reliable cancer registry data:
Greece, Hungary, Liechtenstein, Luxemburg, and Romania. We
excluded Lichtenstein from our analysis, but for the remaining four
countries we extrapolated the age-speciﬁc average cancer incidence
rates of neighboring countries, or from cancer registries in the same
area as the countries selected. The choice of countries used for
extrapolation was the same as that in the Globocan database [13].
Thus for Greece data from Bulgaria, Cyprus, and Central Serbia were
used; for Hungary data from Austria, Croatia, Central Serbia, Slova-
kia, and Slovenia were used; for Luxemburg data from French and
German cancer registries were used; and for Romania data from
Bulgaria, Slovakia, and one regional registry in Romania were used.
In conclusion, our results are referring to a geographical region
of 31 European countries.
2.2. Estimation of the annual number of new selected HPV-related
cancers in Europe
The following HPV-related cancer sites were selected: cervix
(ICD-10 code C53), vulva (C51), vagina (C52), and anus (C21, both
sexes). We estimated the mean annual number of new cancers at
these sites in the selected countries based on the sex- and age-
speciﬁc cancer incidence data available in CI5 Volume X [14], and
extrapolated to the population of each country using 2013 Eurostat
population data (for Italy we used 2012 population data, as 2013
data were not yet available) [15] as follows:
where AIR is the age- and sex-speciﬁc annual incidence rate, and
population is the age- and sex-speciﬁc population. The estimated
numbers of new HPV-related cancer cases for all the selected
countries were then summed to obtain the overall European
burden. Sex-speciﬁc data were available for anal cancer. However,
as preference was given to European data, sex-speciﬁc data were
not used, as they were not considered robust enough due to the
small sample size. When adjusted and crude data were available,
preference was given to adjusted data.
The number of new cancers attributable to HPV overall, to
HPV16/18, and to HPV16/18/31/33/45/52/58 was then estimated
by applying the corresponding cancer site-speciﬁc HPV preva-
lence. Data on HPV prevalence were extracted from the most
relevant published cancer site-speciﬁc data. To avoid overestimat-
ing the prevalence of individual HPV types due to multiple
infections, different adjustment methods, which are described in
the cited paper for each cancer site, were used.
There are other cancers known to be associated with HPV,
including penile cancer in men and a subset of head and neck
cancers in both sexes. We did not estimate the burden of these
cancers in this work, as the currently licensed HPV vaccines don’t
have an indication for cancers at these anatomical sites.
Moreover, the data currently available did not allow us to
calculate the burden associated with the seven high-risk HPV
types targeted by the nine-valent vaccine. Robust studies to
estimate the prevalence of HPV in these cancer sites, and more
speciﬁcally the attributable fraction of the seven high-risk HPV
types targeted by the nine-valent vaccine, are still ongoing.
2.3. Estimation of the annual number of new selected HPV-related
precancerous lesions in Europe
We performed a literature review to retrieve robust age-
speciﬁc incidence data for cervical pre-invasive neoplasia CIN2þ
(including CIN2, CIN3 and adenocarcinoma in situ (AIS), vulvar
intraepithelial neoplasia grades 2 and 3 (VIN2/3), and vaginal
intraepithelial neoplasia grades 2 and 3 (VaIN2/3) in Europe.
Nygard et al. estimated the incidence rates of CIN2þ (including
CIN2/3 and AIS) per 100,000 woman years in 2004–2006, the
period prior to the availability of the quadrivalent vaccine. The
estimates were presented by age group and were age-
standardized using the European standard population. Data were
available for four Nordic countries: Denmark, Iceland, Norway, and
Sweden. Moreover, we had access to incidence data on CIN2þ for
the period 2009–2011 from the French cancer registry of the
Alsace Region, where an organized screening program has been in
place since 1994 in Bas–Rhin and since 2001 in Haut–Rhin
(unpublished data). Based on the data from these ﬁve countries
we estimated incidence rate ranges for CIN2þ by age group, which
we then extrapolated to the combined female population of the 31
included countries. The study by Nygard et al. [16] also contained
incidence data for VIN2/3 and VaIN2/3 by age group from Den-
mark, Iceland, Norway, and Sweden for the period 2004–2006.
However, as only VIN3 and VaIN3 were recorded in Sweden, we
excluded the Swedish data and based our estimates on the data
from the remaining three countries.
We then estimated the number of CIN2þ (including CIN2/3
and AIS), VIN2/3, and VaIN2/3 cases attributable to the HPV types
targeted by the nine-valent vaccine and the quadrivalent vaccine,
respectively. For CIN2þ we applied the site-speciﬁc overall HPV
prevalence, the relative contribution of HPV6/11/16/18, and that of
HPV6/11/16/18/31/33/45/52/58, respectively. As no speciﬁc Eur-
opean data for CIN2þ have yet been published, the authors of the
Total nb of new cases¼
P
Countries
P85þ
age ¼ 0ðAIR in malenpopulationþ
P
type of cancerðAIR in femalenpopulationÞÞ
n o
100;000
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recently published paper [17] kindly provided us with information
speciﬁc to Europe. We applied HPV prevalence and type attribu-
table fractions from published literature for VIN2/3 [18] and
VaIN2/3 [19], as well as additional data we requested from the
authors of these studies. The adjustment methods that were used
to account for multiple infections are described in the cited papers
for each lesion type.
As no age-speciﬁc incidence data are available for anal intrae-
pithelial neoplasia grades 2 and 3 (AIN2/3), we used sex-speciﬁc,
age-standardized incidence rates from the Danish Registry of
Pathology [20] and extrapolated them to the female and the male
population, respectively, of all 31 European countries. The estimated
annual number of AIN2/3 attributable to HPV overall, HPV6/11/16/
18, and HPV6/11/16/18/31/33/45/52/58, respectively, was based on
HPV prevalence data extracted from Alemany et al. [19], as well as
additional data we requested from the authors of that study.
2.4. Estimation of the annual number of new genital warts cases in
Europe
To estimate the annual number of new genital warts cases we
used the methodology previously described [21]. Brieﬂy, two
European publications were identiﬁed that, based on their design,
provided the most robust incidence data for Europe [22,23]. Both
are retrospective cohort studies carried out using databases,
including very large samples of routinely collected data. We
extrapolated the value from each publication to the 2013 popula-
tion of the 31 European countries to provide an estimated range of
the annual number of new genital warts cases in women and men
in Europe. The estimated prevalence of HPV6/11 of 90% in genital
warts was then applied to estimate the number of cases attribu-
table to the HPV types targeted by the nine-valent and quad-
rivalent vaccines.
3. Results
3.1. Women
3.1.1. HPV-related cancers in women
3.1.1.1. Cervical cancer. The estimated annual number of new
cervical cancers in 2013 was 34,708 (95% bound: 32,640–36,793)
in the 31 selected European countries combined. It is generally
accepted that HPV infection is necessary for the development of
cervical cancer [24], thus 100% of these cases are believed to be
HPV-positive. HPV16/18 are the predominant types in cervical
cancer, accounting for 72.8% (95% CI: 70.8–74.7) of cases [10];
high-risk HPV16/18/31/33/45/52/58 were estimated to be
responsible for 89.0% (95% CI: 87.5–90.3) of cases in Europe
(Table 1). Accordingly, a total of 25,267 (95% bound: 23,062–
27,528) cases were estimated to be attributable to HPV16/18
versus 30,890 (95% bound: 28,539–33,242) cases attributable to
HPV16/18/31/33/45/52/58. The estimated annual number of new
cervical cancer cases attributable to the ﬁve new HPV types
targeted by the nine-valent vaccine (HPV31/33/45/52/58) was
thus 5623 (95% bound: 4681–6640) (Table 2).
3.1.1.2. Vulvar cancer. The estimated annual number of new vulvar
cancers was 9544 (95% bound: 8509–10,596). Given the overall
HPV prevalence in vulvar cancer in Europe of 19.3% (95% CI: 16.7–
22.0) [18], 1842 (95% bound: 1377–2381) cases were estimated to
be attributable to HPV. The relative contribution of HPV16/18 and
HPV16/18/31/33/45/52/58 were estimated at 73.6% (95% CI: 66.4–
79.9) and 84.0% (95% CI: 77.6–89.0), respectively [18] (Table 1).
After applying these relative contribution estimates, 1356 (95%
bound: 903–1911) cases were estimated to be attributable to
HPV16/18 versus 1547 (95% bound: 1061–2124) cases
attributable to HPV16/18/31/33/45/52/58. The estimated annual
number of new vulvar cancer cases associated with the ﬁve new
HPV types targeted by the nine-valent vaccine (HPV31/33/45/52/
58) was thus 193 (95% bound: 71–401) (Table 2).
3.1.1.3. Vaginal cancer. The estimated annual number of new vaginal
cancer cases was 2171 (95% bound: 1676–2684). Of these cases, 1544
(95% bound: 1046–2107) are estimated to be attributable to HPV,
assuming an overall HPV prevalence in vaginal cancer of 71.1% (95%
CI: 63.2–78.1) in Europe [25]. The relative contribution of HPV16/18
and HPV16/18/31/33/45/52/58 was estimated to be 71.2% (95% CI:
61.8–79.6) and 85.6% (95% CI: 77.1–91.3), respectively (Table 1).
Applying these values, 1099 (95% bound: 635–1685) cases were
estimated to be attributable to HPV16/18 versus 1322 (95% bound:
799–1927) cases attributable to HPV16/18/31/33/45/52/58. Thus the
estimated annual number of new vaginal cancers in Europe
associated with the ﬁve new HPV types targeted by the nine-valent
vaccine was 222 (95% bound: 69–483) (Table 2).
3.1.1.4. Anal cancer. The estimated annual number of new anal
cancer cases was 4562 (95% bound: 3875–5265) among women in
Europe, irrespective of HPV status. Given the overall HPV
prevalence in anal cancer of 87.6% (95% CI: 81.6–92.1) [19], 3996
cases (95% bound: 3151–4855) were estimated to be attributable
to HPV. The relative contribution of HPV16/18 in HPV-positive anal
cancers was estimated at 87.1% (95% CI: 80.7–92.1) and the relative
contribution of HPV16/18/31/33/45/52/58 at 89.8% (95% CI: 83.8–
94.2). After applying these values, 3481 (95% bound: 2533–4477)
cases were estimated to be attributable to HPV16/18 versus 3589
(95% bound: 2632–4577) attributable to HPV16/18/31/33/45/52/58
(Table 1). Thus an additional 108 (95% bound: 13–356) cases were
estimated to be attributable to the ﬁve new HPV types targeted by
the nine-valent vaccine (Table 2).
3.1.2. HPV-related precancerous lesions in women
3.1.2.1. Cervical intraepithelial neoplasia grade 2 or worse. Age-
standardized incidence rates of CIN2þ (including CIN2/3 and
AIS) in the ﬁve countries for which data were available ranged
between 138.8 (Norway) and 183.2 (Iceland) per 100,000 woman-
years (Appendix A). Incidence was very low in the youngest age
group (o20 years) in the four Nordic countries considered (there
were no data available for this age group in France, where cervical
cancer screening starts at age 25 years) [16]. However, in Iceland,
where organized cervical cancer screening begins at 20 years of
age, incidence rates in this age group were slightly higher, and the
highest rates were observed from age 20 to 30 years. After the age
of 50 years age-speciﬁc incidence rates in Iceland were the lowest
of the four Nordic countries considered.
All CIN is HPV-related, with HPV6/11/16/18 accounting for 23–
25% of CIN1, 38.4–39% of CIN2, and 58% of CIN3. The HPV types
targeted by the nine-valent vaccine account for 46–51% of CIN1,
71–74.3% of CIN2 and 85–90% of CIN3 (worldwide data) [17]
(Table 3). Based on the age-speciﬁc incidence rates, the estimated
annual number of new CIN2þ cases in women in Europe ranged
between 267,350 and 510,609. 45.5% and 82.3% of these cases were
estimated to be attributable to the HPV types targeted by the
quadrivalent vaccine (HPV6/11/16/18) and nine-valent vaccine
(HPV6/11/16/18/31/33/45/52/58), respectively [17 with additional
information on European data kindly provided by the authors]
(Table 3, (Fig. 2). After applying these values, 121,644 to 232,327 of
the 267,350 to 510,609 new annual CIN2þ cases were estimated to
be attributable to HPV6/11/16/18 versus 220,029 to 420,231 cases
for HPV6/11/16/18/31/33/45/52/58. Therefore an additional 98,385
to 187,904 CIN2þ cases annually are estimated to be related to the
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Table 1
Overall HPV prevalence and the relative contributiona of HPV16/18 and HPV16/18/31/33/45/52/58 by cancer site.
Cancer
site
ICD-10
code
HPV prevalence
%, (95% CI)
HPV16/18 attributable fraction
among HPVþ cases %, (95% CI)
HPV 16/18/31/33/45/52/58 attributable
fraction among HPVþ cases%, (95% CI)
HPV 31/33/45/52/58 attributable
fraction among HPVþ cases%
Reference
Cervix C53 100 72.8 (70.8–74.7) 89.0 (87.5–90.3) þ 16.2 (14.6–17.8) de Sanjosé
et al. [10]
Vulva C51 19.3 (16.7–22.0) 73.6 (66.4–79.9) 84.0 (77.6–89.0) þ 10.5 (6.2–15.9) de Sanjosé
et al. [18]
Vagina C52 71.1 (63.2–78.1) 71.2 (61.8–79.6) 85.6 (77.1–91.3) þ 14.4 (7.9–21.9) Alemany
et al. [25]
Anus C21 87.6 (81.6–92.1) 87.1 (80.7–92.1) 89.8 (83.8–94.2) þ 2.7 (0.7–6.8) Alemany
et al. [19]
HPV: human papillomavirus; ICD-10: International Classiﬁcation of Diseases, 10th Revision; CI: conﬁdence interval.
a Adjusted for multiple infections.
Table 2
Estimated mean annual number of new HPV-related cancer cases in women and men in Europe.
Cancer site N of new cancers
irrespective of HPV status
(95% bound)
N of new cancers
attributable to HPV (95%
bound)
N of new cancers
attributable to HPV16/18
(95% bound)
N of HPV16/18/31/33/45/
52/58þ cancers (95%
bound)
N of cases attributable to additional
types (9v vaccine vs 2v/4v vaccine)
Cervical
cancer
34,708 (32,640–36,793) 34,708 (32,640–36,793) 25,267 (23,062–27,528) 30,890 (28,539–33,242) 5623 (4681–6640)
Vulvar cancer 9,544 (8,509–10,596) 1,842 (1,377–2,381) 1,356 (903–1,911) 1,547 (1,061–2,124) 193 (71–401)
Vaginal
cancer
2,171 (1,676–2,684) 1,544 (1,046–2,107) 1,099 (635–1,685) 1,322 (799–1,927) 222 (69–483)
Anal cancer
(F)
4,562 (3,875–5,265) 3,996 (3,151–4,855) 3,481 (2,533–4,477) 3,589 (2,632–4,577) 108 (13–356)
Total
(women)
50,985 (47,018–54,983) 42,090 (38,436–45,863) 31,203 (27,319–35,353) 37,347 (33,230–41,609) 6146 (4880–7780)
Anal cancer
(M): Total
(men)
2,729 (2,195–3,279) 2,390 (1,783–3,025) 2,082 (1,431–2,790) 2,147 (1,487–2,852) 65 (6–226)
Total (both
sexes)
53,714 (49,296–58,165) 44,480 (40,294–48,795) 33,285 (28,818–38,055) 39,494 (34,787–44,372) 6210 (4892–7981)
% 100 83 62 74 12
HPV: human papillomavirus; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia; AIN: anal intraepithelial
neoplasia; CI: conﬁdence interval.
Table 3
Overall HPV prevalence and the relative contributiona of HPV6/11/16/18 and HPV6/11/16/18/31/33/45/52/58 by precancerous lesion.
Precancerous
lesion
HPV
prevalence %,
(95% CI)
HPV6/11/16/18 attributable
fraction HPVþ cases %, (95%
CI)
HPV 6/11/16/18/31/33/45/52/58
attributable fraction among HPVþ cases
%, (95% CI)
HPV 31/33/45/52/58
attributable fraction among
HPVþ cases %
Reference
CIN 1b 100 23–25 51–46 þ23–26 Joura et al. [17]
CIN 2b 100 38.4–39 71–74.3 þ32–35.9 Joura et al. [17]
CIN 3b 100 58 85–90 þ27–32. Joura et al. [17]
CIN 2þc 100 45.5 82.3 þ36.8 Joura et al. [17] with additional
information kindly provided by
the authors
VIN 2/3c 86.9 (82.6–
90.4)
82.2 (77.2–86.6) 94.4 (91.0–96.9) þ12.2 de Sanjosé et al. [18]
VaIN 2/3c 95.8 (91.8–
98.2)
64.1 (56.6–71.2) 77.6 (70.6–83.3) þ13.5 Alemany et al. [25]
AIN 2/3c 95.3 (84.2–
99.4)
75.4 (59.4–87.4) 81.5 (66.4–91.9) þ6.1 Alemany et al. [19]
HPV: human papillomavirus; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia; AIN: anal intraepithelial
neoplasia; CI: conﬁdence interval.
a Adjusted for multiple infections.
b Worldwide data.
c European data.
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ﬁve new HPV types included in the nine-valent vaccine (31/33/45/
52/58) (Table 4).
3.1.2.2. Vulvar intraepithelial neoplasia grades 2 and 3. The age-
standardized incidence rates of VIN2/3 in the three Nordic countries
for which data were available ranged between 4.8 (Norway) and 8.8
(Iceland) per 100,000 woman-years (Appendix B). Based on the
age-speciﬁc incidence data from these countries, the estimated
annual number of new VIN2/3 cases in Europe was estimated at
between 13,886 and 27,592. Of these cases 86.9% (95% CI: 82.6–
90.4) are believed to be HPV-related, with HPV16/18 accounting for
82.2% (95% CI: 77.2–86.6) and HPV16/18/31/33/45/52/58 accounting
for 94.4% (95% CI: 91.0–96.9) of HPV-positive cases [18] (Table 3,
Fig. 2). Based on these estimates, 12,067 to 23,977 of the VIN2/3
cases were estimated to be HPV-positive, with 9919 to 19,709 cases
attributable to HPV16/18 versus 11,391 to 22, 635 attributable to
HPV16/18/31/33/45/52/58. Thus the estimated annual number of
new VIN2/3 cases associated with the ﬁve new HPV types included
in the nine-valent vaccine ranged between 1472 and 2925 in
women in Europe (Table 4).
3.1.2.3. Vaginal intraepithelial neoplasia grades 2 and 3. Age-
standardized incidence rates of VaIN2/3 in the three Nordic
countries for which data were available ranged between 0.9
(Norway) and 1.3 (Iceland) per 100,000 woman-years (Appendix C).
Based on age-speciﬁc incidence data from these countries, the
estimated annual number of new VaIN2/3 cases in women in
Europe ranged between 2549 and 4719. Of these cases, 95.8% (95%
CI: 91.8–98.2) are expected to be HPV-related, with HPV16/18
accounting for 64.1% (95% CI: 56.6–71.2) and HPV16/18/31/33/45/52/
58 accounting for 77.6% (95% CI: 70.6–83.3) of HPV-positive cases [25]
(Table 3, Fig. 2). Based on these estimations, 2442 to 4521 of the 2549
to 4719 new annual VIN2/3 cases were expected to be HPV-positive,
with 1566 to 2898 cases attributable to HPV16/18 versus 1895 to 3508
cases attributable to HPV16/18/31/33/45/52/58. The estimated annual
number of new VaIN2/3 cases associated with the new HPV types
included in the nine-valent vaccine (HPV31/33/45/52/58) thus ranged
between 330 and 610 (Table 4).
3.1.2.4. Anal intraepithelial neoplasia grades 2 and 3. Based on the
age-standardized rate of 0.58 (per 100,000 person-years) for AIN2/
3 in women [20], 1545 new AIN2/3 cases were estimated to occur
each year in women in the 31 European countries. Of these cases,
95.3% (95% CI: 84.2–99.4%) are believed to be HPV-related [19].
Applying these values resulted in 1472 cases attributable to HPV,
with 75.4% (95% CI: 59.4–87.4) and 81.5% (95% CI: 66.4–91.9)
attributable to the HPV types targeted by the quadrivalent and
the nine-valent vaccine, respectively (Table 3, Fig. 2),
corresponding to 1110 and 1200 cases, respectively (Table 4).
3.1.3. Genital warts
The most robust data on the incidence of genital warts come
from Germany and the United Kingdom. Based on these studies, a
lower incidence estimate of 142.0 per 100,000 woman-years [23]
and an upper estimate of 191.1 per 100,000 woman-years [22]
were extracted, and so the estimated annual number of new
genital wart cases in women in Europe ranged between 378,141
and 508,893. Assuming an HPV6/11 prevalence in genital warts of
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Table 4
Estimated annual number of new CIN2þ , VIN 2/3, VaIN 2/3 and AIN 2/3 cases in women and men in Europe.
Precancerous
lesion
N of new precancerous lesions
irrespective of HPV status
N of cases
attributable to
HPV
N of cases related to
quadrivalent vaccine types
(range)
N of cases related to nine-
valent vaccine types (range)
Additional N of cases
related to ﬁve new HPV
types
CIN 2þ 267,350–510,609 267,350–510,609 121,644–232,327 220,029–420,231 98,385–187,904
VIN 2/3 13,886–27,592 12,067–23,977 9,919–19,709 11,391–22,635 1,472–2,925
VaIN 2/3 2,549–4,719 2,442–4,521 1,566–2,898 1,895–3,508 329–610
AIN 2/3 (F) 1,545 1,472 1,110 1,200 90
AIN 2/3 (M) 1,093 1,042 786 849 63
Total (both
sexes)
286,423–545,558 284,373–541,621 135,025–256,830 235,364–448,423 100,339–191,592
% 100 99 47 82 35
HPV: human papillomavirus; CIN: cervical intraepithelial neoplasia; CIN 2þ includes CIN2/3 and AIS; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial
neoplasia; AIN: anal intraepithelial neoplasia; N: number.
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90% [2], between 340,327 and 458,003 of these cases were
estimated to be attributable to HPV6/11 (Table 5).
3.2. Men
3.2.1. HPV-related cancers
3.2.1.1. Anal cancer. The estimated annual number of new anal
cancers in men in Europe was estimated at 2729 (95% bound:
2195–3279), irrespective of HPV status. Given the overall HPV
prevalence of 87.6% (95% CI: 81.6–92.1) in anal cancer [19], 2390
(95% bound: 1783–3025) of these cases were estimated to be
attributable to HPV. The relative contribution of HPV16/18 in HPV-
positive anal cancer has been estimated at 87.1% (95% CI: 80.7–
92.1), with the relative contribution of HPV16/18/31/33/45/52/58
at 89.8% (95% CI: 83.8–94.2). After applying these values, 2082
(95% bound: 1431–2790) cases were estimated to be attributable
to HPV16/18 versus 2147 (95% bound: 1487–2852) attributable to
HPV16/18/31/33/45/52/58 (Table 1), thus an additional 65 (95%
bound: 6–226) cases were estimated to be attributable to ﬁve new
HPV types included in the nine-valent vaccine (Table 2).
3.2.2. HPV-related precancerous lesions
3.2.2.1. Anal intraepithelial neoplasia grades 2 and 3. Based on the
age-standardized rate of AIN2/3 in men of 0.43 [20], 1093 new
AIN2/3 cases were expected to occur each year in men in the 31
European countries and an 95.3% (95% CI: 84.2–99.4%) of AIN2/3
are HPV-related [19]. This rendered 1042 cases, with 75.4% (95%
CI: 59.4–87.4) and 81.5% (95% CI: 66.4–91.9) attributable to the
HPV types targeted by the quadrivalent and the nine-valent
vaccine, and corresponded to an estimated annual number of
786 and 849 cases, respectively (Tables 3 and 4).
3.2.3. Genital warts
The most robust data on the incidence of genital warts come
from Germany [22] and the United Kingdom [23]: Based on these
studies, a lower incidence estimate of 147.66 per 100,000 man-
years and an upper estimate of 167.7 per 100,000 man-years were
extracted, and so the estimated annual number of new genital
wart cases in men in Europe ranged between 375,467 and
426,425. Assuming an HPV6/11 prevalence in genital warts of
90% [2], between 337,921 and 383,782 of these cases were
estimated to be attributable to HPV6/11 (Table 5).
4. Discussion
Our estimates demonstrate the high burden of cancer and
precancerous lesions associated with the HPV types targeted by
the new nine-valent HPV vaccine (HPV6/11/16/18/31/33/45/52/58)
that are expected to occur every year in women and men in
Europe. Overall, 39,494 (95% bound: 34,787 to 44,372) of the
53,714 (95% bound: 49,296 to 58,165) new HPV-related cancers of
the cervix, vulva, vagina, and anus in women and men in Europe
are expected to be associated with the high-risk HPV types
included in the nine-valent vaccine, versus 33,285 (95% bound:
28,818 to 38,055) associated with high-risk HPV16/18. This repre-
sents an additional 6210 cancer cases (95% bound: 4892–7981),
corresponding to a relative increase of 19% (Fig. 3).
The proportion of cervical cancer attributable to the seven
high-risk HPV types targeted by the nine-valent vaccine is similar
worldwide. The combined relative contribution of these seven
high-risk types in Europe was 89.0% (95% CI: 87.5–90.3) compared
to worldwide values of 89.4% (95% CI: 88.8–90.1), which range
from 84.6% (95% CI: 81.9–87.1) in Central America to 95.5% (95% CI:
91.2–98.2) in North America [26].
Furthermore, the estimated annual number of new cases of
precancerous lesions occurring inwomen and men in Europe (CIN2/
3þAIS, VIN2/3, VaIN2/3 and AIN2/3) was 286,423 to 545,558, with
284,373 to 541,621 HPV-positive cases. Of these, 235,364 to 448,423
cases are associated with HPV6/11/16/18/31/33/45/52/58 versus
135,025 to 256,830 associated with HPV6/11/16/18. The ﬁve new
HPV types 31/33/45/52/58 were thus associated with an additional
100,339 to 191,592 cases per year, corresponding to a relative
increase of 75% (Table 4, (Fig. 4). We did not estimate the expected
annual number of new low-grade precancerous lesions of the cervix
(CIN1). Indeed, no robust incidence data are available on CIN1 as
these cases are not usually reported to cancer registries, and a high
amount of this cases regress spontaneously. Thus records of CIN1
incidence very much depend on the national screening system and
cannot be extrapolated. Even if CIN1 is not currently considered a
precancerous lesion, the potential psychological and economic
impact (due to medical follow-up) on affected women is very
important. The additional number of CIN1 cases related to the ﬁve
new HPV types 31/33/45/52/58 is expected to be very high, as
Table 5
Estimated annual number of new genital wart cases in women and men in Europe.
N of new annual cases
(range)
N of new annual cases related to
HPV6/11 (range)
Women 378,141–508,893 340,327–458,003
Men 375,467–426,425 337,921–383,782
Total (both
sexes)
753,608–935,318 678,248–841,785
HPV: human papillomavirus; N: number.
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vaccine. HPV: human papillomavirus.
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worldwide 46–51% of CIN1 are related to the HPV types targeted by
the nine-valent vaccine compared to 23–25% for the quadrivalent
vaccine types [17].
As previously mentioned, there are other cancers known to be
associated with HPV, including penile cancer in men and a subset of
head and neck cancers in both sexes. The currently licensed HPV
vaccines don’t have an indication for cancers at these anatomical
sites and up to now efﬁcacy of the vaccines against these cancers has
not been demonstrated. However, it can be expected that future
studies based on routine use of the vaccines may demonstrate their
efﬁcacy against head and neck cancers and penile cancers.
Based on the above described methodology we estimated the
overall burden of head and neck cancers in women and men and
penile cancer in men in Europe. 17,676 new head and neck cancer
cases were estimated to occur every year in women, with 2089
and 1915 related to second and ﬁrst generation vaccine types,
respectively. For men the number of head and neck cancers was
80,062, of which 7911 were related to second and 7144 cases to
ﬁrst generation vaccine types. The burden of penile cancer was
4096 this region with 1070 and 932 cases related to second and
ﬁrst generation vaccines, respectively (work in progress). These
data are preliminary, as the key studies estimating the prevalence
of HPV at these sites, and more speciﬁcally the attributable
fraction of the seven high-risk HPV types targeted by the nine-
valent vaccine, are still ongoing. The data currently available in the
literature are very heterogeneous, as only a subset of head and
neck cancers is HPV-related, and many other risk factors exist, like
alcohol and tobacco consumption, which differ from region to
region. Moreover, differences in the results of HPV prevalence
between studies might be due to contamination and the variability
of HPV detection methods. Studies considering more accurate
biomarkers of oncogenic HPV activity, such as E6/E7 mRNA or
p16INK4a in addition to HPV DNA prevalence, are still ongoing.
Recurrent respiratory papillomatosis is also highly associated
with HPV. It is a very rare disease, which is difﬁcult to treat and
has high recurrence rates. However, incidence data in Europe are
scarce [27], and thus it was not possible to estimate the number of
new annual cases in Europe. Low-risk HPV6/11 are prevalent in
virtually all cases [27,28]. and no additional burden is expected to
be associated with the ﬁve new HPV types.
4.1. Strengths and limitations
A short-term prediction method was used to estimate the
number of new cancer cases in 2013 from the most recent data
collected from 2003 to 2007. Therefore these estimates were
accurate only if the incidence rates of the cancers under study
remained stable over time. In the case of increasing incidence, they
would slightly underestimate the expected number of cases, and
the opposite would be true in the case of decreasing incidence.
As mentioned above, the CI5 database contains national cancer
incidence rates for 19 European countries. Eight of the countries
included in this report had only regional incidence rates available,
which were extrapolated to the entire country. Although we assessed
the geographical coverage and distribution of these regional regis-
tries, other factors could vary and inﬂuence regional incidence rates.
For the remaining four countries no robust regional or national data
were available. We thus extrapolated the mean incidence data from
surrounding cancer registries to these countries, but we had no
means to check the robustness of this method. Therefore the results
should thus be interpreted with particular caution.
For some cancer sites additional tests such as p16 or mRNA had
been performed to conﬁrm causality in the presence of HPV DNA
(lack of data availability). Indeed, the mere presence of HPV is
insufﬁcient to prove causation, as the infection may be transient
and not related to the carcinogenic process. Therefore our applica-
tion of previously published HPV prevalence to an estimated
number of new cancer cases may have yielded an overestimation
of cases attributable to HPV.
Our calculations were based on the relative contribution
estimates extracted from one study per cancer site. However, for
each cancer site we selected the study with the most robust design
and a large sample size, and that provided individual data allowing
weighting for multiple infections. We used only European data
and, when available, adjusted data rather than crude data. Sex-
speciﬁc data for HPV prevalence in anal cancers were available, but
we decided not to use it, as sample size by sex was not sufﬁcient to
obtain meaningful, precise estimates. In any case, there were no
sizeable differences between the data for both sexes. It was not
possible to compare the extracted data to results from meta-
analyses, as to our knowledge no meta-analysis contains informa-
tion about multiple infections in precancerous lesions, and thus
the relative contribution of individual HPV types, taking multiple
infection into account (i.e., to avoid double counting) could not be
estimated. A literature search that we performed in parallel
showed large differences in the prevalence of the different HPV
types between studies and regions. However, it is not clear if these
differences are due to real differences in the distribution of HPV
types among European women, or to differences in HPV detection
methods. Furthermore, most of the published studies contained no
information about individual multiple infections or had low
sample sizes. The calculation of a robust relative contribution of
speciﬁc types was thus not possible based on these data, as it
would have provided less meaningful results.
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The method used to calculate the estimated annual number of
new CIN cases also has some limitations. For CIN2þ we based our
estimations on data extracted from one published epidemiological
study covering four Nordic countries and one French study (unpub-
lished). To calculate the estimated annual number of new CIN2þ
cases in women in Europe we extrapolated the lower and the upper
mean value of each age group to the population of each included
European country. However, the incidence of CIN may vary
throughout Europe, not only due to regional differences in the
prevalence of HPV, but also due to different screening and preven-
tion methods.
In Iceland for example, screening starts at age 20, with a 2-year
interval until age 69. This might explain the high incidence rates
observed in the youngest age groups and lower incidence rates in
the age group over 50 in Iceland compared to the other four
countries (personal communication from Kristján Oddsson).
We used data from countries with well-organized screening,
thus reﬂecting the real high burden of precancerous lesions. By
extrapolating these data to countries without or with less orga-
nized screening, we overestimated the detected burden in those
countries. However these lesions do exist, even if not detected,
and have a high potential to develop to cancer if not recognized
and treated: 5% of CIN2 and more than 12% of CIN3 progress to
invasive cancer [29]. Mc Credie et al. found that the cumulative 30
year incidence of invasive cancer in women with CIN3 was 30%
and increased to 50% in women with persistent CIN3 [30]. There-
fore we consider that the estimation of the detectable burden
(referring to a real but not recognized burden in countries without
or with limited screening) is of high value.
Another limitation is that our estimations of CIN2þ were based
on estimates of the relative contribution of HPV observed in a
population of young women (aged 16 to 26 years), who may have
more multiple infections than older women. The burden of
precancerous lesions is most important in the younger age group,
and in the absence of age-speciﬁc relative contribution estimates,
it seemed appropriate to use the data for all age groups combined.
Finally, it has to be considered that all results on the incidence
of cancers and cervical precancerous lesions in this study have
been estimated in a post-screening context.
The reporting of VIN2/3 and VaIN2/3 might not be exhaustive as
there is no dedicated screening program, thus the reported burden is
probably underestimated. Differences in the incidence of these
lesions were observed between the different countries and it remains
unclear to what extent the observed discrepancies can be explained
by the completeness of registries, differences in clinical practice and
management, or different background risk. Compared to a study
from the Netherlands [31], much higher rates of VIN2/3 were
reported in the study from Nygard et al. [16]. To our knowledge
the data that we used for our estimation are the best data available in
Europe as there is no organized screening and mandatory notiﬁca-
tion for these precancerous lesions. However, the results have to be
considered with caution. Additional studies in the future are neces-
sary to give a better insight on the real burden of these lesions.
5. Conclusions
A total number of 53,714 new cases (95% bound: 49,296–
58,165) of cancers of the cervix, vulva, vagina in women, and anus
in women and men, were estimated to occur in Europe every year,
of which 44,480 (95% bound: 40,294–48,795) were estimated to
be HPV-positive. Of the latter, 89%, i.e., 39,494 cases (95% bound:
34,787–44,372) were estimated to be related to HPV types 16/18/
31/33/45/52/58 versus 75% to HPV16/18, corresponding to 33,285
cases (95% bound: 28,818–38,055).
Additionally, the estimated annual burden of CIN2þ , VIN2/3,
VaIN2/3 in women, and AIN2/3 in women and men ranged
between 286,423 and 545,558 new cases per year, of which 82%
were related to HPV6/11/16/18/31/33/45/52/58 (i.e., 235,364 to
448,423 cases versus 47% related to HPV6/11/16/18), correspond-
ing to 135,025 to 256,830 cases.
In addition to cancers and precancerous lesions, between 753,608
and 935,318 new annual genital warts cases were estimated to occur
in women and men in Europe, of which 90% (between 678,248 and
841,785 cases) were estimated to be related to HPV6/11.
The relative increase in the number of new cancers attributable
to HPV16/18/31/33/45/52/58 compared to HPV16/18 was 19%. For
precancerous lesions this increase was 75% when comparing
HPV6/11/16/18/31/33/45/52/58 and HPV6/11/16/18
These data demonstrate how the large public health impact in
the prevention of cancer that was achieved by the ﬁrst generation
HPV vaccines could be further increased by the second generation
nine-valent HPV vaccine, due to additional cancer prevention and
notably the prevention of precancerous lesion in women.
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